Events

We will be attending the largest gathering for mRNA-dedicated professionals in Europe.

Our Managing Director Tim Sparey will be attending JPM 2023 in the new year.

Our Managing Director Tim Sparey, and Senior Director Alliance Manager Rob Barber, join one of Europe’s largest events for investment and partnering in innovative healthcare to seek out like-minded companies interested in advancing the self-amplifying RNA platform (saRNA) space.

Our Managing Director Tim Sparey will be attending the Inv€$tival Showcase™ in London this year.

Our Managing Director Tim Sparey will be attending the LSX European Lifestars Awards. We are delighted to be finalists in Deal of the Year for our partnership with AstraZeneca to commercialise a saRNA and accelerate our innovative Innate Inhibitory Protein (IIP) platform technology.

Our newly appointed Head of Drug Delivery and Formulation George Dakwar will attend the 10th International mRNA Health Conference, along with Robin Shattock, where they will share expertise with fellow industry experts.

Our Director and Executive Chairman, Mike Watson, will present at the ExcellGene Symposium in Lausanne on 30 August 2022. The Symposium aims to bring together top scientists, thought leaders, regulatory experts, investors and political representatives, covering industry and academia, to discuss vaccine manufacturing bottlenecks and challenges.

Our Managing Director Tim Sparey will be attending the BIO International Convention in San Diego, where he will gain critical insights from global thought leaders addressing critical topics at the intersection of science, business and policy.

Catalyzing the Nanomedicine Revolution

Our Co-Founder, Director and Chief Scientific Officer Robin Shattock will be presenting at the 17th Liposome Research Days in Vancouver on 12-15 June 2022.

Leading international experts will deliver overview lectures that provide a global perspective, and will be available to network with fellow experts, academics and trainees. Researchers and trainees from academia and industry will present the latest research on key topics such as vaccines, gene therapy, gene editing, chemotherapy, and lipid and membrane biophysics.

Our Managing Director Tim Sparey will be attending Bio€quity Europe, to join biopharma leaders debate industry headwinds, and discuss how to gain the upper hand in a global competition for talent and capital.

SMi’s 13th annual RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments of the industry.

Our Managing Director Tim Sparey and Chief Development Officer Elaine Harper are delighted to be attending the mRNA-Based Therapeutics Summit Europe organised by Hanson Wade from the 25th to 27th of January. The conference aims to bring together key opinion leaders from Europe and the rest of the world to delve deep into the challenges associated with successfully designing and developing the next-generation of mRNA-based vaccines & therapeutics with improved specificity, delivery & efficacy for immuno-oncology, infectious diseases and beyond.

Our Director and Executive Chairman, Dr Michael Watson, will be presenting at the 18th Annual bioProcessUK Conference hosted by the BioIndustry Association on Thursday the 25th of November in Cardiff, UK. Mike will be on a panel chaired by Andy Jones from Innovate UK, entitled “What next for pandemic response?” Mike will be giving an in-depth overview of pandemics and how we can get ahead.

The success of the mRNA vaccines has seen surge of interest in RNA technologies. This session will explore some of the non-COVID related therapeutics currently in development, which address other viral diseases such as the flu but also conditions in other therapeutics areas such as oncology.